The present invention relates to a Reg3α polypeptide (also known as hepatocarcinoma-intestinal-pancreatic /
pancreatitis-associated
protein (HIP / PAP)) for protecting
oxygen-sensitive
Gram-positive
bacteria, a composition comprising the polypeptide and its use. The inventors have demonstrated that an increase in the concentration of hReg3α
lectin in the lumen of the
gastrointestinal tract (GIT) of hReg3α transgenic mice induces significant changes in the composition of the intestinal microbiota and significantly improves the host's resistance to
intestinal inflammation. hReg3α has potent
antioxidant activity on intestinal epithelial cells during
colitis, and in particular ROS
scavenging activity, in particular by promoting the survival of hyperoxygen-sensitive
bacteria. The inventors have also demonstrated that, after antibiotic treatment, hReg3α transgenic mice are better resistant to DSS-induced
colitis. Therefore, the present invention relates to a Reg3α polypeptide for protecting
oxygen-sensitive
Gram-positive
bacteria, in particular Ruminococcus family, such as
Faecalibacterium prausnitzii and / or Lachnospiraceae family, such as enteric
Roseburia; a pharmaceutical composition comprising the polypeptide and its use; and the use of this polypeptide for promoting the
in vitro growth of
oxygen-sensitive
Gram-positive bacteria. The Reg3α polypeptide can be used to prevent or treat microbiota-related diseases and / or disorders, in particular selected from
inflammatory bowel disease (IBD),
colitis,
gastrointestinal infections,
irritable bowel syndrome and other gastrointestinal functional diseases,
gastrointestinal cancer,
metabolic syndrome and
obesity, diabetes,
liver disease, allergic diseases, neurodegenerative diseases and psychological disorders.